Comparison of laparoscopic hepatectomy and radiofrequency ablation for small hepatocellular carcinoma patients: a SEER population-based propensity score matching study
Updates in Surgery · 2024-12 · 76 (8) · 2755-2766
DOI: 10.1007/s13304-024-02016-w ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Updates in Surgery, online erschienen am 01.10.2024. Verfasst von Xi Wang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatobiliary Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Hepatectomy, Liver Neoplasms, Propensity Score. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
This study was designed to compare the efficacy of laparoscopic hepatectomy (LH) and radiofrequency ablation (RFA) in terms of their therapeutic effect on small hepatocellular carcinoma (SHCC). The SEER database was employed to integrate SHCC patients who had received treatment with either LH (n = 1132) or RFA (n = 797). The LH group (n = 623) and the RFA group (n = 623) were matched with 1:1 propensity score matching (PSM) in order to reduce the possibility of selection bias. The Kaplan–Meier method and Cox proportional hazards regression method were employed to ascertain the prognostic factors associated with overall survival (OS) and disease-specific survival (DSS). Both before and after PSM, the 1, 3 and 5-years OS and DSS were significantly higher in the LH groups compared to the RFA group. Besides, for SHCC with tumor size ≤ 2cm (n = 418), even P values not reaching statistical significance, the survival curves were compatible with a superiority of LH over RFA for OS and DSS in overall (P = 0.054 and P = 0.077), primary SHCC (P = 0.110 and P = 0.058) and recurrent SHCC (P = 0.068 and P = 1.000) cohorts. In contrast, for SHCC with tumor size between 2 and 3 cm (n = 828), LH group always had a better OS and DSS in the all cohorts (all P < 0.05). In addition, higher AFP level, poor differentiation grade, recurrent tumor and treatment type were independent prognostic factors for OS, while poor differentiation grade, larger tumor size and treatment type were the independent prognostic factors for DSS (all P < 0.05). LH was associated with better OS and DSS than RFA in SHCC patients. Even in tumor size ≤ 2 cm, LH still should be the first choice as its long-term survival benefits.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Hepatobiliary Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
- Department of Hepatobiliary Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. chenqinjunjie@126.com.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Wang, X., Chai, X., Tang, R., Xu, Y., & Chen, Q. (2024). Comparison of laparoscopic hepatectomy and radiofrequency ablation for small hepatocellular carcinoma patients: a SEER population-based propensity score matching study. Updates in Surgery, 76(8), 2755-2766. https://doi.org/10.1007/s13304-024-02016-w
Vancouver
Wang X, Chai X, Tang R, Xu Y, Chen Q. Comparison of laparoscopic hepatectomy and radiofrequency ablation for small hepatocellular carcinoma patients: a SEER population-based propensity score matching study. Updates in Surgery. 2024;76(8):2755-2766. doi:10.1007/s13304-024-02016-w
BibTeX
@article{Wang2024,
author = {Wang, Xi and Chai, Xinqun and Tang, Ruiya and Xu, Yunjie and Chen, Qinjunjie},
title = {Comparison of laparoscopic hepatectomy and radiofrequency ablation for small hepatocellular carcinoma patients: a SEER population-based propensity score matching study},
journal = {Updates in Surgery},
year = {2024},
volume = {76},
number = {8},
pages = {2755--2766},
doi = {10.1007/s13304-024-02016-w}
}
EUVIMED